FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2922183800> ?p ?o ?g. }

• W2922183800 endingPage "2056" @default.
• W2922183800 startingPage "2045" @default.
• W2922183800 abstract "Abstract Background ZTI-01 (fosfomycin for injection) is an epoxide antibiotic with a differentiated mechanism of action (MOA) inhibiting an early step in bacterial cell wall synthesis. ZTI-01 has broad in vitro spectrum of activity, including multidrug-resistant Gram-negative pathogens, and is being developed for treatment of complicated urinary tract infection (cUTI) and acute pyelonephritis (AP) in the United States. Methods Hospitalized adults with suspected or microbiologically confirmed cUTI/AP were randomized 1:1 to 6 g ZTI-01 q8h or 4.5 g intravenous (IV) piperacillin-tazobactam (PIP-TAZ) q8h for a fixed 7-day course (no oral switch); patients with concomitant bacteremia could receive up to 14 days. Results Of 465 randomized patients, 233 and 231 were treated with ZTI-01 and PIP-TAZ, respectively. In the microbiologic modified intent-to-treat (m-MITT) population, ZTI-01 met the primary objective of noninferiority compared with PIP-TAZ with overall success rates of 64.7% (119/184 patients) vs 54.5% (97/178 patients), respectively; treatment difference was 10.2% (95% confidence interval [CI]: −0.4, 20.8). Clinical cure rates at test of cure (TOC, day 19–21) were high and similar between treatments (90.8% [167/184] vs 91.6% [163/178], respectively). In post hoc analysis using unique pathogens typed by pulsed-field gel electrophoresis, overall success rates at TOC in m-MITT were 69.0% (127/184) for ZTI-01 versus 57.3% (102/178) for PIP-TAZ (difference 11.7% 95% CI: 1.3, 22.1). ZTI-01 was well tolerated. Most treatment-emergent adverse events, including hypokalemia and elevated serum aminotransferases, were mild and transient. Conclusions ZTI-01 was effective for treatment of cUTI including AP and offers a new IV therapeutic option with a differentiated MOA for patients with serious Gram-negative infections. Clinical Trial Registration NCT02753946" @default.
• W2922183800 created "2019-03-22" @default.
• W2922183800 creator A5013718821 @default.
• W2922183800 creator A5013759582 @default.
• W2922183800 creator A5027398140 @default.
• W2922183800 creator A5029445024 @default.
• W2922183800 creator A5030399565 @default.
• W2922183800 creator A5031780287 @default.
• W2922183800 creator A5037124848 @default.
• W2922183800 creator A5046046038 @default.
• W2922183800 creator A5055207951 @default.
• W2922183800 creator A5089036530 @default.
• W2922183800 date "2019-03-06" @default.
• W2922183800 modified "2023-10-10" @default.
• W2922183800 title "Fosfomycin for Injection (ZTI-01) Versus Piperacillin-tazobactam for the Treatment of Complicated Urinary Tract Infection Including Acute Pyelonephritis: ZEUS, A Phase 2/3 Randomized Trial" @default.
• W2922183800 cites W1949620401 @default.
• W2922183800 cites W2002116702 @default.
• W2922183800 cites W2019495118 @default.
• W2922183800 cites W2123373935 @default.
• W2922183800 cites W2131455454 @default.
• W2922183800 cites W2166108176 @default.
• W2922183800 cites W2308843652 @default.
• W2922183800 cites W2437593726 @default.
• W2922183800 cites W2519197882 @default.
• W2922183800 cites W2560013005 @default.
• W2922183800 cites W2760064995 @default.
• W2922183800 cites W2793280651 @default.
• W2922183800 cites W4211238209 @default.
• W2922183800 doi "https://doi.org/10.1093/cid/ciz181" @default.
• W2922183800 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6880332" @default.
• W2922183800 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30861061" @default.
• W2922183800 hasPublicationYear "2019" @default.
• W2922183800 type Work @default.
• W2922183800 sameAs 2922183800 @default.
• W2922183800 citedByCount "85" @default.
• W2922183800 countsByYear W29221838002019 @default.
• W2922183800 countsByYear W29221838002020 @default.
• W2922183800 countsByYear W29221838002021 @default.
• W2922183800 countsByYear W29221838002022 @default.
• W2922183800 countsByYear W29221838002023 @default.
• W2922183800 crossrefType "journal-article" @default.
• W2922183800 hasAuthorship W2922183800A5013718821 @default.
• W2922183800 hasAuthorship W2922183800A5013759582 @default.
• W2922183800 hasAuthorship W2922183800A5027398140 @default.
• W2922183800 hasAuthorship W2922183800A5029445024 @default.
• W2922183800 hasAuthorship W2922183800A5030399565 @default.
• W2922183800 hasAuthorship W2922183800A5031780287 @default.
• W2922183800 hasAuthorship W2922183800A5037124848 @default.
• W2922183800 hasAuthorship W2922183800A5046046038 @default.
• W2922183800 hasAuthorship W2922183800A5055207951 @default.
• W2922183800 hasAuthorship W2922183800A5089036530 @default.
• W2922183800 hasBestOaLocation W29221838001 @default.
• W2922183800 hasConcept C126322002 @default.
• W2922183800 hasConcept C141071460 @default.
• W2922183800 hasConcept C168563851 @default.
• W2922183800 hasConcept C2777637488 @default.
• W2922183800 hasConcept C2778193466 @default.
• W2922183800 hasConcept C2778266534 @default.
• W2922183800 hasConcept C2778897966 @default.
• W2922183800 hasConcept C2779384505 @default.
• W2922183800 hasConcept C2779443120 @default.
• W2922183800 hasConcept C2779631663 @default.
• W2922183800 hasConcept C2908647359 @default.
• W2922183800 hasConcept C44249647 @default.
• W2922183800 hasConcept C501593827 @default.
• W2922183800 hasConcept C523546767 @default.
• W2922183800 hasConcept C54355233 @default.
• W2922183800 hasConcept C71924100 @default.
• W2922183800 hasConcept C77411442 @default.
• W2922183800 hasConcept C86803240 @default.
• W2922183800 hasConcept C89423630 @default.
• W2922183800 hasConcept C90924648 @default.
• W2922183800 hasConcept C94665300 @default.
• W2922183800 hasConcept C99454951 @default.
• W2922183800 hasConceptScore W2922183800C126322002 @default.
• W2922183800 hasConceptScore W2922183800C141071460 @default.
• W2922183800 hasConceptScore W2922183800C168563851 @default.
• W2922183800 hasConceptScore W2922183800C2777637488 @default.
• W2922183800 hasConceptScore W2922183800C2778193466 @default.
• W2922183800 hasConceptScore W2922183800C2778266534 @default.
• W2922183800 hasConceptScore W2922183800C2778897966 @default.
• W2922183800 hasConceptScore W2922183800C2779384505 @default.
• W2922183800 hasConceptScore W2922183800C2779443120 @default.
• W2922183800 hasConceptScore W2922183800C2779631663 @default.
• W2922183800 hasConceptScore W2922183800C2908647359 @default.
• W2922183800 hasConceptScore W2922183800C44249647 @default.
• W2922183800 hasConceptScore W2922183800C501593827 @default.
• W2922183800 hasConceptScore W2922183800C523546767 @default.
• W2922183800 hasConceptScore W2922183800C54355233 @default.
• W2922183800 hasConceptScore W2922183800C71924100 @default.
• W2922183800 hasConceptScore W2922183800C77411442 @default.
• W2922183800 hasConceptScore W2922183800C86803240 @default.
• W2922183800 hasConceptScore W2922183800C89423630 @default.
• W2922183800 hasConceptScore W2922183800C90924648 @default.
• W2922183800 hasConceptScore W2922183800C94665300 @default.
• W2922183800 hasConceptScore W2922183800C99454951 @default.
• W2922183800 hasIssue "12" @default.
• W2922183800 hasLocation W29221838001 @default.

• next